Lightpoint Medical's agreement with PartnerTech was signed by both parties in May, and is a major milestone for Lightpoint as they prepare for the launch of LightPath™ later in 2015. “
Lightpoint Medical received an R01 grant of $2.6M million from the US National Cancer Institute. This will support clinical trials of Lightpoint's EnLightTM molecular imaging technology in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK).
Vynca won grand prize at the Silicon Valley Boomer Venture Summit’s Business Plan Competition, June 30 at Santa Clara University. Vynca won a $10,000 award for their care coordination and population management software platform for advanced care planning.
Admetsys has been awarded Top Company by Tech Tour and the European Venture Contest at the 2015 Digital Health Venture Forum and has been nominated to present its Smart Pancreas™ technology for hospitalized diabetics at the 2015 European Venture Summit in Düsseldorf, Germany.
Boston-based Admetsys was the winner of The Venture Forum's ninth annual Five-Minute-Pitch contest, held in Worcester Tuesday. Admetsys CEO Jeff Valk gave the winning presentation, earning the $2,500 first prize and the $1,000 audience choice award.
Briteseed has raised $46,250 in cofounder contributions; significant business plan awards, including $73,500 in cash; $1.15 million raised in seed round using a convertible note.
At the Hatch pitch competition five companies came away victorious including Admetsys. The winners received first round interview at Entrepreneurs Roundtable Accelerator; slots in two other accelerators; credits for services from Microsoft and Amazon; entrepreneur office hours.
Vixiar Medical, Inc. announced today that it was awarded a $200,000 grant by the State of Maryland to accelerate the commercialization of its non-invasive congestive heart failure (CHF) device.
The Biobridge is an implant that has been shown to be able to guide the growth of new lymph channels. This technology can be used as an adjunct to existing treatments for the condition to hopefully improve outcomes. Fibralign has benefited from grants from the DoD and NSF to support a large animal study and develop production tools for making its initial product.
Fibralign's first product, BioBridge, is developed to address Secondary Lymphedema, a global chronic debilitating disease that affects over 120 million people and has no cure. The company successfully completed a large animal study that validated BioBridge-treated diseased lymphatic tissue. Fibralign is now preparing for 510(k) submission and a clinical study.